Stuart Collins Selected Research

Strontium-89

1/2017	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
4/2016	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
1/2016	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stuart Collins Research Topics

Disease

3	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 01/2016
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2016 - 08/2010
1	Pain (Aches) 01/2016
1	Neoplasms (Cancer) 07/2011
1	Infections 09/2008

Drug/Important Bio-Agent (IBA)

3	Strontium-89IBA 01/2017 - 01/2016
3	Zoledronic Acid (Zometa)FDA Link 01/2017 - 01/2016
2	Docetaxel (Taxotere)FDA Link 01/2017 - 04/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2010
1	InterferonsIBA 08/2010
1	Sunitinib (Sutent)FDA Link 08/2010
1	Neutralizing AntibodiesIBA 09/2008
1	EnzymesIBA 09/2008
1	ImmunosorbentsIBA 09/2008

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2017 - 01/2016
1	Castration 01/2016
1	Therapeutics 01/2016
1	Nephrectomy 01/2016
1	Operative Time 07/2011